INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. MTCH
10. CVI

Go back to INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)

January 28, 2025 10:26 AM EST

BTIG analyst Thomas Shrader reiterated a Buy rating and $21.00 price target on INmune Bio Inc. (NASDAQ: INMB)

The analyst comments "The promise of immune therapy in mCRPC remains high, and we see more NK involvement as the most obvious mechanism to add as T-Cell alone approaches (CPIs) have shown correlates of protection, but true clinical benefits remain fleeting. We also see the approach as a good match in prostate cancer as front-line anti-androgen-pathway drugs (Zytiga and Xtandi) are very powerful and tumors that escape these drugs are generally highly mutated and under... More